Skip to content

The Proteomic Study and Early Intervention Study of Carotid Unstable Plaque

The Proteomic Study and Early Intervention Study of Carotid Unstable Plaque

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05622877
Enrollment
300
Registered
2022-11-21
Start date
2023-05-31
Completion date
2024-12-31
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Artery Plaque, Protein; Disease, Traditional Chinese Medicine

Keywords

Traditional Chinese Medicine, proteomic study, carotid atherosclerosis plaques

Brief summary

A study on the prediction model of carotid unstable plaque protein and its early intervention. Protein antibody chip was used to detect the remaining biological samples, and patients with carotid artery unstable plaque with stroke risk were selected for interventional clinical trials. The selected patients were randomly divided into 3 groups, which were treated with Zhu's Wenban Formula (TCM compound granules), Qushi Formula (TCM compound granules) and placebo for 6 months, respectively. The size and number of carotid artery unstable plaques before and after 6 months were observed, and the occurrence of adverse reactions during the intervention period was observed.

Interventions

DRUGQushi Formula

Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.

DRUGZhu's Wenban Formula

Zhu's Wenban granules are decoction granules composed of leech, panax notoginseng, Atractylodes Lancea and rhizome

DRUGplacebo

The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.

OTHERBasic treatment

Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.

Sponsors

Guangzhou University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Wet syndrome scale assessment is consistent with wet syndrome diagnosis; * Carotid color ultrasound indicated carotid artery unstable plaque. * Protein chip analysis determined that the patients were at high risk of stroke * Signing informed Consent

Exclusion criteria

* Carotid artery stenosis rate ≥50%; * A definite or suspected diagnosis of vasculitis; * Accompanied by infection, tumor, heart, liver and renal insufficiency (liver and * kidney function more than twice the upper limit of normal value, cardiac function grade greater than or equal to 2); * Patients with acute stroke or complicated with acute myocardial infarction and unstable angina pectoris; * Pregnant or lactating women; * A prior known allergy to the test drug or the test drug ingredient.

Design outcomes

Primary

MeasureTime frameDescription
Changes in carotid artery unstable plaque6 mothsChanges in carotid IMT and the total volume and number of unstable plaques before and after 6 months of treatment

Secondary

MeasureTime frameDescription
Changes in blood lipids6 mothsThe changes of triglyceride, total cholesterol, low density lipoprotein and high density lipoprotein before and after 6 months of treatment;
Number of new cardiovascular events12 mothsNumber of cardiovascular and cerebrovascular events during 6 months of treatment and 6 months of follow-up

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026